Leflunomide, a novel immunomodulating agent, prevents the development of allergic sensitization in an animal model of allergic asthma

Clinical and Experimental Allergy

Volumn 28, Issue 3, 1998, Pages 376-384

  Eber, E ^a   Uhlig, T ^a   McMenamin, C ^a   Sly, P D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Acute phase reaction; Allergen bronchial provocation tests; Immunoglobulins; Immunomodulators; Isoxazoles

Indexed keywords

HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; LEFLUNOMIDE; TERIFLUNOMIDE;

ACUTE PHASE RESPONSE; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; ASTHMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOMODULATION; LUNG FUNCTION TEST; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RAT; SENSITIZATION;

ALLERGENS; ANIMALS; ASTHMA; BRONCHIAL PROVOCATION TESTS; CELL DEGRANULATION; DIMERCAPROL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTAMINE RELEASE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MAST CELLS; OVALBUMIN; RATS; RATS, INBRED BN; RESPIRATORY FUNCTION TESTS;

EID: 0031904885     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.00240.x     Document Type: Article

References (53)

1. International Consensus Report on Diagnosis and Treatment of Asthma. Eur Respir J 1992; 5:601-41.
2. Holt PG, Sly PD. Allergic respiratory diseasel: strategic targets for primary prevention during childhood. Thorax 1997; 52:1-4.
3. e. Proc Natl Acad Sci USA 1988; 85:6880-4.
4. Kaliner M. Asthma and mast cell activation. J Allergy Clin Immunol 1989; 83:510-20.
5. Howarth PH, Durham SR, Lee TH et al. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provacation in asthma. Am Rev Respir Dis 1985; 132:986-92.
6. Cockroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cormoglycate, and beclomethasone diproprionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness o histamine. J Allergy Clin Immun 1987; 79:734-40.
7. Bartlett RR, Campion G, Musikic P. et al. Leflunomide: A novel immunomodulating drug. In Nonsteroidal anti-inflammatory drugs. Mechanisms and clinical uses. AJ Lewis, Furst DE, eds. New York, Basel, Hong Kong: Marcel Dekker, Inc., 1989: 349-66.
8. Popovic S, Barlett RR. Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents Actions 1986; 19:313-14.
9. Thoenes GH, Sitter T, Langer KH, Bartlett RR, Schleyberach R. Leflunomide (HWA 486) inhibits experimental autoimmune rubulointerstitial nephritis in rats. In J Immunopharmacol 1989; 11:921-9.
10. Giant TT, Mikecz K, Barklett RR et al. Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacology 1992; 23:1'05-16.
11. Bartlett RR, Anagnostopulos H, Xielinski T, Mattar T, Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 1993; 14:381-94.
12. Küchle CC, Thoenes GH, Langer KH et al. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23:1083-6.
13. Ulrichs K, Kaitschick J, Bartlett RR, Müller-Ruchholtz W. Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide. Transplant Proc 1992; 24:718-9.
14. Schorlemmer HU, Seiler FR, Bartlett RR. Prolongation of allogenetic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxaszol derivative. Transplant Proc 1993; 25:763-7.
15. Williams JW, Xiao F, Foster P. et al. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57:1223-31.
16. Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995; 38:1595-603.
17. Bartlett RR, Mattar T, Weithmann U et al. Leflunomide (HWA 486): a novel immunorestoring drug. In: Lewis AJ, Doherty NS, Ackerman NR, eds. Therapeutic approaches to inflammatory diseases. New York: Elsevier Science Publishing 1989; 215-28.
18. Nicolai T, Lanteri CJ, Freezer N, Sly PD. Non-invasive determination of alveolar pressure during mechanical ventilation. Eur Respir J 1991; 4:1275-83.
19. Lanteri CJ, Willet K, Kano S et al. changes in lung mechanics over the first hour of life in preterm lambs: the effects of intra-uterine steroid treatment. Am J Respir Crit Care med 1994; 150:759-65.
20. Van Halteren AGS, van der Cammen MJF, Biewenga J, Savelkoul HFJ, Kraal G. IgE and mast cell responses upon intestinal allergen exposure. A murine model to study the onset of food allergy. J Allergy Clin Immunol 1997; 91:94-9.
21. Sedgwick JD, Holt PG. Induction of IgE-isotype specific tolerance by passive stimulation of the respiratory mucosa. Immunology 1983; 50:635-30.
22. Pearce FL, Blum U, Poblete-Freundt G, Schmutzler W. Studies on the release of histamine from isolated guinea pig mast cells stimulated by ionophore A23187 or by the anaphylactic reaction. N-S Arch Pharmacol 1978; 302:165-72.
23. Holt PG, Warner LA, Papadimitriou JM. Alveolar macrophages: functional heterogeneity within macrophage populations from rat lung. Aust J Exp Biol Med Sci 1982; 60:607-18.
24. Eidelman DH, Bellofiore S, Martin JG. Late airway responses to antigen challenge in sensitized inbred rats. Am Rev Respir Dis 1988; 137:1033-7.
25. Elwood W, Lötvall JO, Barnes PJ, Chung KF. Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized Brown-Norway rats. J Allergy Clin Immunol 1991; 88:951-60.
26. Martin JG, Xu LJ, Toh MY, Olivenstein R, Powell WS. Leukotrienes in bile during the early and the late airway responses after allergen challenge of sensitized rats. Am Rev Respir Dis 1993; 147:104-10.
27. Smith SR, Petillo J. IgE production in rive inbred rat strains following immunization with alum-precipitated egg albumin. Int Arch Allergy Appl Immunol 1976; 52:21-31.
28. Pauwels R, Bazin H, Platteau B, van der Straeten M. The influence of antigen dose on IgE production in different strains. Immunology 1979; 36:151-7.
29. Underwood SL, Kemeny DM, Lee TH, Raeburn D, Karlsson JA. IgE production, antigen-induced airway inflammation and airway hyperreactivity in the Brown Norway rat: the effects of ricin. Immunology 1995; 85:256-61.
30. + T cells in vivo deferentially modulates interleukin-4 and interferon-gamma but not interleukin-2 production by splenic T cells. Immunology 1993; 78:513-9.
31. Djukanovic R, Roche WR, Wilson JW et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142:434-57.
32. Murphy KR, Wilson MC, Irvin CG et al. The requirement for polymorphonuclear leukocytes in the late asthmatic response and heightened airways reactivity in an animal model. Am Rev Respir Dis 1986; 134:62-8.
33. Melewicz FM, Kline LE, Cohen AB, Spiefelberg HL. Characterization of Fc receptor for IgE on human alveolar macrophages. Clin Exp Immunol 1982; 49:364-70.
34. Knauer KA, Lichtenstein LM, Adkinson NF, Fish JE. Platelet activation during antigen-induced airway reactions in asthmatic subjects. N Eng J Med 1981; 304:1404-7.
35. Lai CKW, Holgate ST. The mast cell in asthma. In: Kay AB, ed. Clinical immunology and allergy: the allergic basis of asthma. London: Balliere Tindall 1988; 37-65.
36. Bradding P, Feather IH, Howarth PH et al. Interleukin 4 is localised to and released by human mast cells. J Exp Med 1992; 176:1381-6.
37. Bradding P., Roberts JA, Britten KM et al. Interleukin-4, 5, and -6 and tumor necrosis factor-in normal and asthmatic airways: evidence for the human mast cell as a source ocf these cytokines. Am J Respir Cell Mol Biol 1994; 10:471-80.
38. Kips JC, Tavernier J, Pauwels RA. Tumor necrosis factor (TNF) causes bronchial hyperresponsiveness in rats. Am Rev Respir Dis 1992; 145:332-6.
39. Finkelman FD, Katona IM, Urban Jr. JF et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988; 141:2335-41.
40. 2. Proc Natl Acad Sci USA 1988; 85:6880-4.
41. Bissonnette EY, Enciso JA, Befus AD. Inhibition of tumour necrosis factor-alpha (TNF-alpha release from mast cells by the anti-inflammatory drugs, sodium cromoglycate and nedocromil sodium. Clin Exp Immunol 1995; 102:78-84.
42. Rubinchik E, Norris A, Levi-Schaffer F. Modulations of histamine release from mast cells by interleukin-2 is affected by nedocromil sodium. Int J Immunopharmaco 1995; 17:563-70.
43. Casolaro V, Spadaro G, Patella V, Marone G. In vivo characterization of the anti inflammatory effects of cyclosporin A on human basophils. J Immunol 1993; 151:5563-73.
44. Wershil BK, Furuta GT, Lavigne JE et al. Dexamethasone and cyclosporin A suppress mast cell-leukocyte cytokine cascades by multiple mechanisms. Int Arch Allergy Imm 1995; 107:323-4.
45. Maxwell DL, Hawksworth RJ, Ledd TH. Inhaled nedocromil sodium reduces histamine release from isolated large airway segments of asthmatic subjects in vivo. Eur Respir J 1993; 6:1145-50.
46. Mattar T, Kochhar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334:161-4.
47. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270:12398-403.
48. Zeilinski T, Zeitter D, Mullner S, Bartlett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflamm Res 1995; 44, Supplement 2: S207-S208.
49. Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ransom JT. Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995: 44:317-22.
50. Williamson RA, Yea CM, Robson PA et al. Dihydroorate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulating compound. J Biol Chem 1995; 270:22467-72.
51. Zuber RH, Lowenthal JW, Erard F et al. Activated B-cells express receptors for and proliferate in response to pure interleukin 2. J Exp Med 1984; 160:1170-83.
52. Cooper KD. New therapeutic approaches in atopic dermatitis. Clin Rev Allergy 1993; 11:543-59.
53. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153:509-14.